PIA
MYGN icon

Piedmont Investment Advisors’s Myriad Genetics MYGN Stock Holding History

Piedmont Investment Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-18,462
Closed -$613K – 1140
2019
Q1 		$613K Buy
18,462
+654
+4% +$19.9K 0.02% 445
2018
Q4 		$518K Buy
17,808
+1,368
+8% +$49.2K 0.02% 451
2018
Q3 		$756K Sell
16,440
-53,739
-77% -$2.39M 0.03% 372
2018
Q2 		$2.62M Buy
70,179
+1,285
+2% +$43.4K 0.13% 169
2018
Q1 		$2.04M Buy
68,894
+658
+1% +$22.3K 0.05% 258
2017
Q4 		$2.34M Sell
68,236
-676
-1% -$22.8K 0.05% 241
2017
Q3 		$2.49M Sell
68,912
-61,113
-47% -$1.74M 0.05% 232
2017
Q2 		$3.36M Buy
130,025
+45,512
+54% +$966K 0.07% 222
2017
Q1 		$1.62M Buy
84,513
+48,036
+132% +$851K 0.03% 261
2016
Q4 		$608K Buy
36,477
+23,139
+173% +$419K 0.01% 296
2016
Q3 		$274K Buy
13,338
+13,310
+47,536% +$338K 0.01% 359
2016
Q2 		$856 Hold
28
– – ﹤0.01% 381
2016
Q1 		$1.05K Hold
28
– – ﹤0.01% 369
2015
Q4 		$1.21K Hold
28
– – ﹤0.01% 377
2015
Q3 		$1.05K Hold
28
– – ﹤0.01% 385
2015
Q2 		$951 Hold
28
– – ﹤0.01% 395
2015
Q1 		$991 Hold
28
– – ﹤0.01% 306
2014
Q4 		$953 Sell
28
-22
-44% -$781 ﹤0.01% 309
2014
Q3 		$1.93K Buy
50
+3
+6% +$112 ﹤0.01% 249
2014
Q2 		$1.83K Hold
47
– – ﹤0.01% 292
2014
Q1 		$1.61K Sell
47
-66
-58% -$2.04K ﹤0.01% 303
2013
Q4 		$2.37K Buy
113
+99
+707% +$2.5K ﹤0.01% 274
2013
Q3 		$329 Buy
+14
New +$398 ﹤0.01% 304

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Piedmont Investment Advisors's MYGN Position: Q2 2019 in Review

Piedmont Investment Advisors sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 18,462 shares — an estimated $613K sold.

Piedmont Investment Advisors first reported a position in MYGN in Q3 2013 and held it in 23 quarters. The position peaked at $3.36M in Q2 2017. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

  • Piedmont Investment Advisors reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
  • Piedmont Investment Advisors sold 18,462 Myriad Genetics shares in Q2 2019, an estimated $613K.
  • Piedmont Investment Advisors first reported a position in Myriad Genetics in Q3 2013 and held it in 23 quarters.
  • Piedmont Investment Advisors's Myriad Genetics position peaked at $3.36M in Q2 2017.
  • 235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Piedmont Investment Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.